Press Releases UCB SA OTC Markets

Equities

UCBJY

US9034801012

Market Closed - OTC Markets Other stock markets 01:24:15 18/05/2024 am IST			5-day change	1st Jan Change
67.62 ^USD	+2.70%		+2.24%	+55.09%

11/04	Berenberg Reiterates UCB's Purchase Rating, Raises PT	MT
11/04	UCB : Berenberg, Buy, raises its price target	CF

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

UCB : Transparency notification Wellington	17/05	PU
UCB : Acquisition of own shares	17/05	PU
UCB - Acquisition of own shares	13/05	AQ
UCB : Acquisition of own shares	10/05	PU
UCB presents final open-label extension F data at International Child Neurology Congress Annual Meeting	09/05	AQ
UCB : presents final open-label extension F®▼(fenfluramine) data at International Child Neurology Congress (ICNC) Annual Meeting	08/05	PU
UCB - Acquisition of own shares	06/05	AQ
UCB : Acquisition of own shares	26/04	PU
Pioneering innovation, fueling growth: UCB's commitment to delivering differentiated solutions	26/04	PU
UCB : General Meeting of Shareholders 2024	25/04	PU
UCB : receives European Commission approval for BIMZELX▼(bimekizumab) as the first IL-17A and IL-17F biologic for moderate to severe hidradenitis suppurativa	22/04	PU
UCB : FINTEPLA▼ (fenfluramine) oral solution approved in Japan for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS)	17/04	PU
UCB presents new data highlighting developments across expansive neurology portfolio at 76th American Academy of Neurology Annual Meeting	15/04	AQ
UCB : Latest real-world evidence presented at WCO-IOF-ESCEO assesses how EVENITY▼ (romosozumab) can help to close the treatment gap in osteoporosi	12/04	PU
UCB : presents new data highlighting developments across expansive neurology portfolio at 76th American Academy of Neurology (AAN) Annual Meeting	12/04	PU
UCB : Acquisition of own shares - 2024	06/04	PU
UCB : FDA Accepts Supplemental Biologics License Applications for BIMZELX (bimekizumab-bkzx) for Moderate to Severe Hidradenitis Suppurativa and Additional 2mL Device Presentations	04/04	PU
Share Repurchase Program 2024 to cover UCB's Long Term Incentive Plans for employees	01/04	AQ
UCB : Share Repurchase Program 2024 to cover UCB's Long Term Incentive Plans for employees	30/03	PU
UCB : receives positive CHMP opinion for BIMZELX▼(bimekizumab) for the treatment of adults with moderate to severe hidradenitis suppurativa	22/03	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

UCB : UCB all set to reach new highs

March 08, 2024 at 09:40 pm IST